{"id":1007074,"date":"2026-09-30T08:36:03","date_gmt":"2026-09-30T12:36:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/"},"modified":"2026-09-30T08:36:03","modified_gmt":"2026-09-30T12:36:03","slug":"autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/","title":{"rendered":"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance"},"content":{"rendered":"
\n

\n FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months<\/i>\n <\/p>\n

\n THE WOODLANDS, TX, Sept. 30, 2026 (GLOBE NEWSWIRE) — <\/b>
\n Autonomix Medical, Inc.<\/a>\u202f(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d),\u00a0a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the Company\u2019s recently announced standalone transvascular sensing platform, which is designed to detect and differentiate faint biological signals.<\/p>\n

The FDA interaction provided important guidance regarding Autonomix\u2019s proposed regulatory strategy, validation activities and anticipated submission pathway for the Company\u2019s standalone sensing platform. Based on feedback received, the Company believes it has identified a Class II regulatory pathway that would use an already-cleared reference device to support a substantial-equivalence strategy for its standalone sensing platform.<\/p>\n

Subject to successful completion of development and validation activities, and FDA review, Autonomix is targeting potential U.S. clearance in approximately 15 months.<\/p>\n

\u201cThis FDA interaction gives us greater clarity on the work required to pursue an initial U.S. clearance and represents a significant milestone in advancing our proprietary technology toward the U.S. market,\u201d said Brad Hauser, Chief Executive Officer of Autonomix. \u201cWe believe a focused pathway for the standalone sensing platform allows us to pursue a nearer-term regulatory objective, while we continue to build toward the larger opportunity for our technology. Our goal is to establish the sensing foundation first, then expand toward biosignal interpretation and, over time, procedural guidance.\u201d<\/p>\n

Autonomix believes successful clearance of the standalone sensing platform could establish a regulatory predicate supporting future generations of its technology platform, including planned signal interpretation and procedular guidance capabilities.<\/p>\n

\u201cOur vision is a clear progression: sense, interpret and ultimately guide,\u201d continued Mr. Hauser. \u201cThe ability to capture extremely faint biosignals at their source is the critical first step. From there, we believe we can build increasingly powerful computational capabilities, including artificial intelligence, designed to help physicians understand what is happening physiologically, where intervention may be appropriate and what changed following treatment. We believe this staged approach is a disciplined path from standalone sensing toward a broader ‘Sense, Treat and Verify’ platform. We look forward to sharing more in the coming months about how we plan to advance these capabilities.\u201d<\/p>\n

The Company will continue development and validation activities associated with its standalone sensing platform while advancing signal interpretation and other advanced computational capabilities for future generations of its platform.<\/p>\n

\n About Autonomix Medical, Inc.\u00a0<\/b>\n <\/p>\n

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company\u2019s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.<\/p>\n

Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
\u00a0
For more information, visit\u00a0autonomix.com<\/a>\u00a0and connect with the Company on\u00a0X<\/a>,\u00a0LinkedIn<\/a>,\u00a0<\/u>Instagram<\/a>\u00a0and\u00a0Facebook<\/a>.
\u00a0<\/b>
Forward Looking Statements\u00a0<\/b><\/p>\n

Some of the statements in this release are \u201cforward-looking statements,\u201d which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as \u201cshould,\u201d \u201cmight,\u201d \u201cmay,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cforecasts,\u201d \u201cexpects,\u201d \u201cplans,\u201d and \u201cproposes.\u201d Forward-looking statements in this press release include, but are not limited to, expectations regarding the Company\u2019s anticipated regulatory pathway and strategy for its standalone sensing platform, including the potential for Class II clearance based on substantial equivalence, the anticipated timeline for potential U.S. clearance, the potential for a cleared standalone sensing platform to serve as a regulatory predicate for future product generations, the Company\u2019s staged development plans for its platform, including potential signal interpretation and AI-enabled capabilities, the potential effectiveness and clinical benefits of Autonomix\u2019s nerve-targeted treatments for pancreatic cancer pain and other conditions, the versatility and scalability of the Company\u2019s platform technology, the potential for future clinical applications across multiple organ systems, and the strength and scope of the Company\u2019s intellectual property portfolio.<\/p>\n

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading \u201cRisk Factors\u201d and elsewhere in the most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.<\/p>\n

\n Investor and Media Contact\u00a0<\/b>\n <\/p>\n

JTC Team, LLC\u00a0
Jenene Thomas
908.824.0775
autonomix@jtcir.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months THE WOODLANDS, TX, Sept. 30, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc.\u202f(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d),\u00a0a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the Company\u2019s recently announced standalone transvascular sensing platform, which is designed to detect and differentiate faint biological signals. The FDA interaction provided important guidance regarding Autonomix\u2019s proposed regulatory strategy, validation activities and anticipated submission pathway for the Company\u2019s standalone sensing platform. Based on … <\/p>\n

Continue reading “Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1007074","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAutonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months THE WOODLANDS, TX, Sept. 30, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc.\u202f(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d),\u00a0a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the Company\u2019s recently announced standalone transvascular sensing platform, which is designed to detect and differentiate faint biological signals. The FDA interaction provided important guidance regarding Autonomix\u2019s proposed regulatory strategy, validation activities and anticipated submission pathway for the Company\u2019s standalone sensing platform. Based on … Continue reading "Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-30T12:36:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjMwNCM3ODcwMjA5IzUwMDExOTk5Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance\",\"datePublished\":\"2026-09-30T12:36:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/\"},\"wordCount\":886,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjMwNCM3ODcwMjA5IzUwMDExOTk5Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/\",\"name\":\"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjMwNCM3ODcwMjA5IzUwMDExOTk5Mg==\",\"datePublished\":\"2026-09-30T12:36:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjMwNCM3ODcwMjA5IzUwMDExOTk5Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjMwNCM3ODcwMjA5IzUwMDExOTk5Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/","og_locale":"en_US","og_type":"article","og_title":"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance - Market Newsdesk","og_description":"FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months THE WOODLANDS, TX, Sept. 30, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc.\u202f(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d),\u00a0a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the Company\u2019s recently announced standalone transvascular sensing platform, which is designed to detect and differentiate faint biological signals. The FDA interaction provided important guidance regarding Autonomix\u2019s proposed regulatory strategy, validation activities and anticipated submission pathway for the Company\u2019s standalone sensing platform. Based on … Continue reading \"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-30T12:36:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjMwNCM3ODcwMjA5IzUwMDExOTk5Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance","datePublished":"2026-09-30T12:36:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/"},"wordCount":886,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjMwNCM3ODcwMjA5IzUwMDExOTk5Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/","name":"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjMwNCM3ODcwMjA5IzUwMDExOTk5Mg==","datePublished":"2026-09-30T12:36:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjMwNCM3ODcwMjA5IzUwMDExOTk5Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjMwNCM3ODcwMjA5IzUwMDExOTk5Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-reports-positive-fda-feedback-supporting-510k-pathway-to-u-s-clearance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1007074"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007074\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1007074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1007074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1007074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}